Opthea (OPT) Stock Price, News & Analysis

Company Overview

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Key Stats

• Today's Range: $3.25 to $3.48
• 50-Day Range: $3.41 to $3.41
• 52-Week Range: $1.79 to $6.30
• Volume: 3,000 shs
• Average Volume: N/A
• Market Capitalization: $524.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.33
• Consensus Rating: Hold

OPT Stock Analysis - Frequently Asked Questions

How have OPT shares performed this year?

Opthea's stock was trading at $3.93 at the beginning of the year. Since then, OPT stock has decreased by 13.2% and is now trading at $3.41.

When did Opthea IPO?

Opthea (OPT) raised $161 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

How do I buy shares of Opthea?

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Opthea own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST), Zendesk (ZEN) and Adobe (ADBE).

Company Calendar

• Today: 8/04/2025
• Next Earnings (Estimated): 8/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPT
• CIK: 1815620
• Web: www.opthea.com
• Phone: 61-3-9826-0399
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Opthea: $1.33
• High Price Target: $2.00
• Low Price Target: $1.00
• Potential Upside/Downside: -60.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.57
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $120 thousand
• Price / Sales: 4,373.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.56) per share
• Price / Book: -6.09

Miscellaneous

• Outstanding Shares: 153,910,000
• Free Float: 148,986,000
• Market Cap: $524.83 million
• Optionable: Not Optionable
• Beta: 1.17